Calcium pyrophosphate deposition (CPPD) disease is secondary to the pathological accumulation of calcium pyrophosphate (CPP) crystals inside joints and involves acute or chronic inflammatory arthritis. Epidemiological research on CPPD has been slow despite the suspected high prevalence of this condition. Here we highlight key challenges in CPPD imaging, diagnosis and nomenclature that need to be addressed for epidemiological research to progress at a faster pace.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Pascart, T. et al. Calcium pyrophosphate deposition disease. Lancet Rheumatol. 6, e791–e804 (2024).
Tedeschi, S. K. et al. Imaging features of calcium pyrophosphate deposition disease: consensus definitions from an international multidisciplinary working group. Arthritis Care Res. 75, 825–834 (2023).
Cipolletta, E. et al. The diagnostic value of conventional radiography and musculoskeletal ultrasonography in calcium pyrophosphate deposition disease: a systematic literature review and meta-analysis. Osteoarthritis Cartilage 29, 619–632 (2021).
Mandl, P. et al. 2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice. Ann. Rheum. Dis. 83, 752–759 (2024).
Tedeschi, S. K. et al. A prospective study of dual-energy CT scanning, US and X-ray in acute calcium pyrophosphate crystal arthritis. Rheumatology 59, 900–903 (2020).
Abhishek, A. et al. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Ann. Rheum. Dis. 75, 1703–1713 (2023).
Bartels, C. M., Singh, J. A., Parperis, K., Huber, K. & Rosenthal, A. K. Validation of administrative codes for calcium pyrophosphate deposition: a Veterans Administration study. J Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis. 21, 189–192 (2015).
Pascart, T. et al. Features associated with different inflammatory phenotypes of calcium pyrophosphate deposition (CPPD) disease: study using data from the international ACR/EULAR CPPD classification criteria cohort. Arthritis Rheumatol. 76, 1780–1788 (2024).
Jauffret, C. et al. Systematic literature review on calcium pyrophosphate deposition (CPPD) nomenclature: condition elements and clinical states— A Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus project. RMD Open. 11, e004847 (2025).
Tedeschi, S. K. A new era for calcium pyrophosphate deposition disease research: the first-ever calcium pyrophosphate deposition disease classification criteria and considerations for measuring outcomes in calcium pyrophosphate deposition disease. Gout Urate Cryst. Depos. Dis. 2, 52–59 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Rights and permissions
About this article
Cite this article
Jauffret, C., Pascart, T. Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition. Nat Rev Rheumatol 21, 312–313 (2025). https://doi.org/10.1038/s41584-025-01256-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41584-025-01256-3